Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

A review of natural immunity, vaccines, and variants in SARS-CoV-2 reinfection

In a literature review article published in the Journal of Community Hospital Internal Medicine Perspectives, authors from the US performed a thorough investigation of previous studies and case reports of SARS-CoV-2 reinfection. This review discusses the role of natural immunity, vaccines, and SARS-CoV-2 variants in reinfection.

25 Nov 2021

Study explores adverse effects of SARS-CoV-2-induced antibody responses

The authors of a research paper published in the journal Frontiers in Immunology used Sandwich ELISA tests to determine the distribution of IgG sub-classes and complement activation levels in plasma from convalescent individuals.

25 Nov 2021

Researchers reveal possible role for anti-idiotype antibodies in long-term effects of COVID-19

With around 256 million cases and more than 5 million deaths worldwide, the COVID-19 pandemic has challenged scientists and those in the medical field.

25 Nov 2021

Using metal nanoparticles to fight SARS-CoV-2

A recent review article looks at the potential of nanotechnology in fighting severe acute respiratory syndrome 2 (SARS-CoV-2), with several possibilities of strategies in therapeutics, vaccines, and prevention.

25 Nov 2021

COVID-19 vaccine boosters to prevent breakthrough SARS-CoV-2 infections in healthy adults

Researchers measured anti-RBD IgG and virus neutralization before and after vaccination with boosters.

25 Nov 2021

Researchers investigate Moderna COVID-19 vaccine efficacy

Researchers have been investigating the vaccine efficacy of the mRNA-1273 vaccine.

25 Nov 2021

Breakthrough infections from SARS-CoV-2 Delta variant among vaccinated healthcare workers

A new study published on the medRxiv* preprint server employed in-silico techniques, combining genomic and epidemiological data, to determine possible Delta-variant transmission events between vaccinated healthcare workers (HCWs) in Indian hospitals.

25 Nov 2021

Serum SARS-CoV-2 antigen: A better predictor of COVID-19 severity

In this perspective, a new study published on the medRxiv* preprint server analyzed the clinical efficacy of two serum antigen tests to identify SARS CoV-2 infection and evaluate the kinetics of serum nucleocapsid (N) antigen in severe and non-severe patients for disease severity prediction.

24 Nov 2021

Study compares immune responses of patients with and without kidney failure after COVID-19 vaccination

Death rates from COVID-19 are especially high in individuals with kidney failure who are on dialysis, making SARS-CoV-2 vaccination in this population a high priority.

24 Nov 2021

Acute SARS-CoV-2 infection during pregnancy associated with placental ACE2 shedding

A new study, published on the bioRxiv* preprint server, hypothesized that ACE-2 expression and ADAM17 activity in the placenta is affected by the timing of SARS-CoV-2 infection of the mother.

24 Nov 2021

SARS-CoV-2 reinfection and the natural immune response

Researchers review available literature on immunity and SARS-CoV-2 infection to elucidate mechanisms behind SARS-CoV-2 immunity and reinfections.

24 Nov 2021

New technique may be a significant leap forward in the understanding of human cells

Most human diseases can be traced to malfunctioning parts of a cell — a tumor is able to grow because a gene wasn't accurately translated into a particular protein or a metabolic disease arises because mitochondria aren't firing properly, for example. But to understand what parts of a cell can go wrong in a disease, scientists first need to have a complete list of parts.

24 Nov 2021

CIRM awards $4.1 million to advance CAR T-cell therapy from the lab to clinic

On November 23, 2021, the California Institute for Regenerative Medicine (CIRM) governing board approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.

24 Nov 2021

Similar antibody responses to spike protein in COVID-19 survivors and vaccine recipients

Researchers conducted a study on COVID-19 convalescent patients and post-vaccinated populations to identify the minimal levels of antibody required to protect against SARS-CoV-2 infection.

24 Nov 2021

Antibody persistence in infants after maternal COVID-19 vaccination

New research finds COVID-19 vaccination during pregnancy results in significantly greater antibody persistence in the infants compared to natural infection of the mothers during pregnancy.

24 Nov 2021

Bat coronavirus ecology, evolution, and spillover

In a review published in Nature Reviews Microbiology, the authors collate information about the ecology and evolution of bat coronaviruses.

24 Nov 2021

Limited immune responses three months after Pfizer-BioNTech vaccination among elderly

In this study, published on the medRxiv* preprint server, the humoral response to SARS-CoV-2 was assessed before and after three months of administration of the BNT162b2 mRNA COVID-19 vaccination (Pfizer-BioNTech). In addition, elders' humoral responses were compared to those of a younger group, and a functional neutralization experiment against the Wuhan-Hu-1 (WH1) virus and the Delta variant was carried out.

23 Nov 2021

Vaccine-induced immune responses for SARS-CoV-2 in patients receiving anti-CD20 B-cell depleting therapies

A new study published on the medRxiv* preprint server analyzed the trajectories of anti-SARS-CoV-2 antibodies in patients from the RituxiVac study were compared to healthy volunteers. In addition, they investigated the immunogenicity of a third vaccine dose in previously non-responding patients.

23 Nov 2021

Higher antibody level correlates with greater vaccine protection against COVID-19

By measuring antibodies against the SARS-CoV-2 spike protein in participants in a phase 3 trial of the Moderna COVID-19 vaccine, researchers found that the higher the antibody level, the greater the vaccine protection against COVID-19.

23 Nov 2021

Strong antibody responses against harmless coronaviruses may protect against SARS-CoV-2

Infections with the novel coronavirus and vaccination lead to strong antibody responses against SARS-CoV-2. Immune responses to other human coronaviruses, which mostly only cause harmless colds, also provide some protection against SARS-CoV-2.

23 Nov 2021

Antibody News and Research

Further Reading

A review of natural immunity, vaccines, and variants in SARS-CoV-2 reinfection

Study explores adverse effects of SARS-CoV-2-induced antibody responses

Researchers reveal possible role for anti-idiotype antibodies in long-term effects of COVID-19

Using metal nanoparticles to fight SARS-CoV-2

COVID-19 vaccine boosters to prevent breakthrough SARS-CoV-2 infections in healthy adults

Researchers investigate Moderna COVID-19 vaccine efficacy

Breakthrough infections from SARS-CoV-2 Delta variant among vaccinated healthcare workers

Serum SARS-CoV-2 antigen: A better predictor of COVID-19 severity

Study compares immune responses of patients with and without kidney failure after COVID-19 vaccination

Acute SARS-CoV-2 infection during pregnancy associated with placental ACE2 shedding

SARS-CoV-2 reinfection and the natural immune response

New technique may be a significant leap forward in the understanding of human cells

CIRM awards $4.1 million to advance CAR T-cell therapy from the lab to clinic

Similar antibody responses to spike protein in COVID-19 survivors and vaccine recipients

Antibody persistence in infants after maternal COVID-19 vaccination

Bat coronavirus ecology, evolution, and spillover

Limited immune responses three months after Pfizer-BioNTech vaccination among elderly

Vaccine-induced immune responses for SARS-CoV-2 in patients receiving anti-CD20 B-cell depleting therapies

Higher antibody level correlates with greater vaccine protection against COVID-19

Strong antibody responses against harmless coronaviruses may protect against SARS-CoV-2

Accelerating therapeutic antibody discovery and development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo